| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c06bc0c2d1b16f9d16470b7e30874649 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4025
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4025
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-10 |
| filingDate |
2014-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d1fd1d6ec406f8c13c822e50e03fdef8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a830a0aa4897220fb5c8e6d52cbb3f03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3050bf2ac575d8be29551c32e80ebd9d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3bdc8d4ce869d79cfccdfb1a2581dc41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a1405c5d19afcc5848c27f4d687dd046 |
| publicationDate |
2015-09-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
TW-201534297-A |
| titleOfInvention |
Drug combination for treating melanoma |
| abstract |
The invention relates to a pharmaceutical combination for treating melanoma comprising a cyclin-dependent kinase (CDK) inhibitor and at least one anticancer agent, wherein the CDK inhibitor is (as described herein) a compound of formula I Or a pharmaceutically acceptable salt thereof, the at least one anticancer agent is selected from a BRAF inhibitor or a MEK inhibitor. The invention also relates to a method for treating melanoma comprising administering to a subject in need thereof a therapeutically effective amount of a CDK inhibitor and a therapeutically effective amount of at least one anticancer agent selected from the group consisting of a BRAF inhibitor or MEK inhibitor. |
| priorityDate |
2013-07-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |